BRISTOL ONCOLOGY PORTFOLIO EXPANDS BEYOND CYTOTOXIC DRUGS, LED BY GMK VACCINE: TAXOL ANALOGS BEING DEVELOPED TO IMPROVE ACTIVITY, SAFETY PROFILE
Executive Summary
Bristol-Myers Squibb's first oncology product outside of its cytotoxic antitumor drug franchise is likely to be its ganglioside-based GMK cancer vaccine, VP-Clinical Cancer Research Renzo Canetta, MD, indicated to analysts at Bristol's Princeton, N.J. facility Dec. 5.